UroGen Pharma Ltd. — Director's Dealing 2021

Dec 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2021-11-30

Reporting Person: Smith Jason Drew (General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-30	Ordinary Shares	M	8333	—	Acquired	10833	Direct
2021-11-30	Ordinary Shares	S	3803	$12.03	Disposed	7030	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-30	Restricted Stock Units	$	M	8333	Disposed		Ordinary Shares (8333)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer

F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units

F3: 1/3 of the shares underlying the restricted stock units will vest on each of November 30, 2021, August 31, 2022 and August 31, 2023.